Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Related Questions
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
In a patient who underwent cryoablation for early NSCLC, is there a role for giving preemptive further local therapy?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Is there any role for adjuvant radiotherapy for resected multistation N2 atypical carcinoid tumor of the lung?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
What radiation treatment volume would you include in chemoradiation given for perihilar lymph node recurrence after surgical resection and mediastinal lymph node dissection for NSCLC?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
Would you offer SBRT as an alternative to surgery for an atypical carcinoid lung tumor?
